Ysios Capital, a venture capital firm based in Barcelona and member of CataloniaBio & HealthTech, today announces its third fund with a committed amount of €155 million and a final target size of €200 million.
Throughout its 12 years of experience, Ysios Capital has invested in 26 companies and managed €346 million through three funds: Ysios BioFund I (€65 million), Ysios BioFund II Innvierte (€126 million) and Ysios BioFund III (€155 million) open to new investors.
Ysios BioFund III will invest in up to 15 companies, mainly in Europe, that develop disruptive therapeutic products and platform technologies to address clear medical needs. The initial investment will range between € 5 and 10 million.
"In the context of the current Covid-19 pandemic, the biotechnology sector has become even more relevant as one of the key sectors that will prepare society for new health threats” say Joël Jean-Mairet and Julia Salaverria, partners of Ysios Capital.
The team has been reinforced with five venture partners and internationally renowned experts: Toni Ribas, president of the American Association for Cancer Research (AACR); Pamela Klein, former VP Development at Genentech-Roche; Carlos Paya, previously in various leadership roles at Eli Lilly; Peter H. Andersen, former Executive VP at Lundbeck, and David L. Lacey, former Senior VP and Global Head of Discovery Research of Amgen.
Photo: Joël Jean-Mairet, in an archive picture from when he won the 2019 CataloniaBio & HealthTech Biosuccess Award.
You may also be interested in:
Comentaris